Navigation Links
Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema

nd we look forward to working with the FDA on an expedited review of our license application," commented Judson Cooper, Chairman of Lev.

"The successful outcome of this trial is a credit to our clinical investigators, our clinical and regulatory team, and, most importantly, the HAE patient community and its leaders who have been so supportive of our efforts," said Joshua D. Schein, Ph.D., the company's Chief Executive Officer.

About Hereditary Angioedema

HAE, or hereditary C1-inhibitor deficiency, is a genetic disorder characterized by recurrent attacks of inflammation affecting the extremities (the hands and feet), the face, the urogenital tract, the abdomen, and the larynx. The inflammation can be disfiguring, debilitating, or, in the case of laryngeal attacks, life-threatening. HAE is caused by a deficiency of the plasma protein C1-INH. While there is no approved therapy for acute attacks in the U.S., the Company believes that replacement therapy with C1-INH is the treatment of choice for HAE in Europe, where it has been used to treat acute HAE attacks for more than 30 years. There are estimated to be 10,000 people with HAE in the United States.

About Lev Pharmaceuticals, Inc.

Lev is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. The Company is currently conducting a registrational Phase III clinical trial of its lead product candidate, C1-INH for the acute and prophylactic treatment of HAE. Lev is also evaluating the development of C1-INH for the treatment of cardiovascular disease and other diseases and disorders in which inflammation is known or believed to play an underlying role. Lev's C1-INH has been granted orphan drug status for the treatment of HAE by the FDA, potentially securing, upon approval, market exclusivity for seven years.

Patients and physicians interested in obtaining more information about Lev's studies for heredit
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:9/19/2014)... , Sept. 19, 2014 Kiromic, LLC, a ... of Kent Hance , the former chancellor of Texas ... retired as chancellor in July 2014, after raising $1.2 billion ... that Kent Hance , the most successful chancellor in ... team not only as an investor, but also as our ...
(Date:9/19/2014)... , September 19, 2014 ... by Equipment (Cryotherapy, Heat, therapy, Hydrotherapy), Accessories (Posture Mirror, ... (Hospitals), Advanced technologies - Global Forecast to 2019" ... poised to reach $19,786.3 Million by 2019 from ... 6.8% from 2014 to 2019. Browse ...
(Date:9/19/2014)... , Sept. 19, 2014  4WEB Medical announces ... 3D-printed foot and ankle osteotomy implants on the ... Ankle Society annual meeting in Chicago ... all of a surgeon,s osteotomy needs with 74 size options ... systems had smaller offerings of only 15 to 18 implant ...
Breaking Medicine Technology:Former Texas Tech Chancellor Named New Vice Chairman of the Board of Kiromic, LLC 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 44WEB Medical Unveils 3D-Printed Osteotomy Truss System 2
... ... pay the United States $1.375 million to resolve False Claims Act ... of a sham durable medical equipment (DME) provider, the Justice Department ... MediNet Corp. provided the kickbacks and assistance and, in return, Harborside ...
... Industry Distributors Association (HIDA) announces the launch of a ... value of medical products distribution. , "Nearly one hundred ... delivered by a distributor, yet few people understand the ... it more efficient," said Matthew J. Rowan, HIDA,s president ...
Cached Medicine Technology:Harborside Healthcare to Pay U.S. $1.375 Million to Resolve Allegations of Kickbacks and Sham Durable Medical Services 2
(Date:9/21/2014)... While public health authorities focus on the physical activity ... University of Montreal reveals that for children, playing has ... an activity that is fun, done alone or with ... or pleasure, but also to combat boredom, sadness, fear, ... of play, authorities put aside several aspects of play ...
(Date:9/21/2014)... roasted peanuts are more likely to trigger an allergy ... study involving mice. , The researchers say that specific ... dry roasting process are recognised by the body,s immune ... immune response the next time it sees any peanuts. ... number of people with peanut allergies in the Western ...
(Date:9/21/2014)... The Laboratory Testing Services industry is ... tests on items ranging from consumer and food products ... on operators to ensure the safety and quality of ... of government safety regulations and consumer lawsuits have led ... Although revenue briefly dipped in 2009 as the US ...
(Date:9/21/2014)... "I wanted to be able to obtain a ... energy drinks," said an inventor from Fresh Meadows, N.Y. ... plain, old coffee. That is why I came up ... CHEWING GUM to provide a healthy energy boost that ... nutritious vitamins, minerals and antioxidants. It also features a ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 The ... BHWG) will host a statewide symposium ( tinyurl.com/ILBHC14 ... Veterans, and their Families. Sponsored by the VNA ... Lottery Cash Grant, and Health & Disability Advocates, ... at the Hilton Hotel in Springfield, IL. ...
Breaking Medicine News(10 mins):Health News:Narrow focus on physical activity could be ruining kids' playtime 2Health News:Dry roasting could help trigger peanut allergy 2Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 2Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 3
... LUNA and the Breast Cancer Fund Launch National Campaign to Inspire ... Educate that Prevention is ... be diagnosed with breast cancer in their lifetime. Although 50 percent,of ... sufferers have a genetic history of the disease. LUNA, the ...
... Mich., Oct. 29 American,Physicians Capital, Inc. (Nasdaq: ... has authorized the repurchase of an additional $20,million of ... under Rule 10b5-1,of the Securities Exchange Act of 1934. ... dollars allocated to the 2007 10b5-1 plan,adopted by the ...
... to Ongoing Oncology Program for MDX-1106, PRINCETON, ... Medarex, Inc. (Nasdaq: MEDX ) announced today ... filed with the U.S. Food &,Drug Administration (FDA) ... Ltd.), a fully human anti-PD-1 antibody being,investigated for ...
... the 2007 third quarter includes $1.8 million of first ... commercial products, DUBLIN, Calif., Oct. 29 SuperGen ... the discovery, rapid,development and commercialization of therapies for solid ... third,quarter and nine months ended September 30, 2007. ...
... with first-ever attack, babies, and people with AIDS, guideline ... CT brain scans should be used to screen certain ... the right kind of treatment, according to a new ... The guideline authors analyzed all available scientific evidence on ...
... for evaluating the eyes ability to distinguish object details ... could provide a more accurate way to assess the ... devices and training, according to a Canadian study. The ... illumination targets for testing spatial vision, which the authors ...
Cached Medicine News:Health News:LUNA Pure Prevention Survey Confirms Breast Cancer Misconceptions 2Health News:LUNA Pure Prevention Survey Confirms Breast Cancer Misconceptions 3Health News:American Physicians Capital, Inc. Authorizes Additional $20 Million Share Buyback 2Health News:Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody 2Health News:Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody 3Health News:Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody 4Health News:SuperGen Reports 2007 Third Quarter Financial Results 2Health News:SuperGen Reports 2007 Third Quarter Financial Results 3Health News:SuperGen Reports 2007 Third Quarter Financial Results 4Health News:SuperGen Reports 2007 Third Quarter Financial Results 5Health News:SuperGen Reports 2007 Third Quarter Financial Results 6Health News:SuperGen Reports 2007 Third Quarter Financial Results 7Health News:SuperGen Reports 2007 Third Quarter Financial Results 8Health News:SuperGen Reports 2007 Third Quarter Financial Results 9Health News:SuperGen Reports 2007 Third Quarter Financial Results 10Health News:Certain Seizure Patients Need Emergency CT Scan 2Health News:Test for visual acuity could aid detection, rehabilitation of AMD 2
... Design Holds The Lens Securely During ... Blades Keep The Optic From Being ... Over Release Of The Optic.,Wide Jaw ... During Insertion.,Reusable, Autoclaveable, Made In The ...
... Unique In-Line Footplates Are Turned 90 ... The Diamond Blade While Incising Tissue. ,Special ... Blade Depth Penetration.,Pre-Set Blade Extension Settings ... Retraction And Full Extension.,1mm Wide Snub ...
2.5V Halogen source, fiber-optic delivery, 2.5X magnification....
Pocket-sized instrument with 2.5X magnification....
Medicine Products: